HPV-vaccine and screening programs: The new era of global prevention

Journal of Preventive Medicine and Hygiene

Volumn 50, Issue 2, 2009, Pages 90-95

  Mariani, Luciano ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

HPV vaccine; Primary and secondary prevention; Screening programs

Indexed keywords

AMORPHOUS ALUMINUM HYDROXYPHOSPHATE SULPHATE; AS O4; IMMUNOLOGICAL ADJUVANT; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER SCREENING; CLINICAL PROTOCOL; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEALTH PROGRAM; HUMAN; INFECTION PREVENTION; INTERNATIONAL COOPERATION; OROPHARYNX CANCER; REVIEW; SCREENING TEST; STRATEGIC PLANNING; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

FEMALE; HUMANS; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; WORLD HEALTH;

EID: 70449737950     PISSN: 11212233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. zur Hausen H, de Villiers EM, Gissmann L. Papillomavirus infections and human genital cancer. Gynecol Oncol 1981;12:S124-8.
2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19 (Pubitemid 29406813)
3. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-265 (Pubitemid 34293391)
4. Schiffman M, Castle P, Jeronimo J, Rodriguez A, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007;370:890-907.
5. Frazer I. HPV immunisation. A significant advance in cancer control. Gynecol Oncol 2007;107:S1.
6. The 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007;197:346-355
7. The 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma insitu. Am J Obstet Gynecol 2007;197:340-345
8. Lippman A, Melnychuk R, Shimmin C, Boscoe M. Human papillomavirus, vaccines and women's health: questions and cautions. CMAJ 2007;177:484-487 (Pubitemid 47359772)
9. Gostin LO and De Angelis CD. Mandatory HPV Vaccination. Public Health vs Private Wealth. JAMA 2007;297:1921-1923
10. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63-73.
11. Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;111:278-285 (Pubitemid 38924707)
12. Preuss SF, Klussmann JP, Jungehulsing M, Eckel HE, Guntinas-Lichius O, Damm M. Long-term results of surgical treatment for recurrent respiratory papillomatosis. Acta Otolaryngol 2007; 127:1196-1201
13. Gerein V, Schmandt S, Babkina N, Barysik N, Coerdt W, Pfister H. Human papillomavirus (HPV)-associated gynecological alteration in mothers of children with recurrent respiratory papillomatosis during long-term observation. Cancer Detect Prev 2007;31:276-281 (Pubitemid 47562634)
14. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-527
15. Clifford G, Franceschi S, Diaz M, Muñoz N, Villa LL. HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006;24(Suppl 3):S26-34.
16. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, M.D., Harper DM, Leodolter S et al. for the FUTURE I Investigators! Quadrivalent Vaccine against Human. Papillomavirus to Prevent Anogenital Diseases. N Engl J Med 2007;356:1928-1943
17. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-1927 (Pubitemid 46740302)
18. The Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007;369:1861-1868
19. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM et al. for the HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-2170
20. Hildesheim A, Herrero R, Wacholder S, Rodriguez A, Solomon D, Bratti C et al. for the Costa Rican HPV Vaccine Trial Group. Effect of Human Papillomavirus 16/18 L1 Viruslike Particle Vaccine Among Young Women With Preexisting Infection A Randomized Trial. JAMA 2007;298:743-753
21. Dunne EF, Karem KL, Sternberg MR, Stone R, Unger E, Reeves WC, et al. Seroprevalence of Human Papillomavirus type 16 in children. JID 2005;191:1817-1819 (Pubitemid 40705387)
22. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER for the Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP).MMWR Recomm 2007;56:1-24.
23. Department of health and human services centers for disease control and prevention. Advisory Committee on Immunization Practices. Summary report, February 27-28, 2008 [http://www.cdc.gov/vaccines/recs/acip/downloads/min-feb08. pdf].
24. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000;181:1911-1919.
25. Viscidi R, Schiffman M, Hildesheim A, Herrero R, Castle P, Bratti M, et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica.Cancer Epidemiol Biomarkers Prev 2004;13:324-327
26. de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Munoz N, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007;7:453-459 (Pubitemid 46962343)
27. Skinner RS, Garland S, Stanley M, Pitts M and Quinn M. Human papillomavirus vaccination for the prevention of cervical neoplasia: is it appropriate to vaccinate women older than 26? MJA 2008;188:238-242
28. th International Congress on Infectious Diseases Kuala Lumpur, Malaysia, June 19-22, 2008.
29. Schwarz T, Spaczynski M, Schneider A, Wysocki J, Galaj A, Perona P et al. on behalf of the HPV Study Group for Adult Women. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 2009;27:581-587
30. th International Papillomavirus Congress, November 3-9, 2007 Beijing, (Presentation #PA1-04).
31. Brown D, Kjaer S, Sigurdsson K, Iversen O-E, Hernandez-Avila M, Wheeler C, et al. The Impact of quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic non-vaccine HPV types in generally HPV-naive women aged 16-26 years. JID 2009;199:926-935
32. Wheeler C, Kjaer S, Sigurdsson K, Iversen O-E, Hernandez-Avila M, Perez G, et al. The impact of quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic non-vaccine HPV types in sexually active women aged 16-26 years. JID 2009;199:936-944
33. Jenkins D. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: Importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol 2008;110:S18-25.
34. th International Papillomavirus Conference, May 8-14 2009, Malmö.
35. Zimet GD, Liddon N, Rosenthal SL, Lazcano-Ponce E, Allen B. Psychosocial aspects of vaccine acceptability. Vaccine 2006;24(S3):201-209
36. Garland S, Park S, Ngan HYS, Frazer I, Tay EH, Chen CJ, Bhatla N, et al. The need for public education on HPV and cervical cancer prevention in Asia. Opinions of experts at the AOGlN Conference.Vaccine 2008; 26:5435-5440
37. Di Giuseppe G, Abbate R, Liguori G, Albano L, Angelillo I. Human papillomavirus and vaccination: knowledge, attitudes, and behavioural intention in adolescents and young women in Italy. Br J Cancer 2008;99:225-229
38. Berg A, Atkins D. Screening for cervical cancer. Recommendations and rationale. Guide to Clinical Preventive Services. (2nd ed). US Preventive Services Task Force. Rockville, MD: Agency to Health Care Research and Quality, 2004.
39. Bosch FX, CastellsaguéX and de Sanjosé S. HPV and cervical cancer: screening or vaccination? Br J Cancer 2008;98:15-21.
40. Franco EL, Cuzick J Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine 2008;26(Suppl 1):A16-23.
41. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. for New Technologies for Cervical Cancer Screening Working Group. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 2008;100:492-501.
42. Nieminen P and Anttila A Introducing HPV screening: challenges and fallacies. Acta Obstet Gynecol Scand. 2007;86:1416-1418 (Pubitemid 350135600)
43. Wentzensen N, von Knebel Doeberitz M. Biomarkers in cervical cancer screening. Dis Markers. 2007;23:315-330 (Pubitemid 47015791)
44. Dillner J, Birembaut P, Petry K-U, Szarewski A, Munk C, de Sanjose S, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008;337:a1754.
45. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007;13:28-41. (Pubitemid 46057835)
46. Goldie S. A public health approach to cervical cancer control: considerations of screening and vaccination strategies. Int J Gynecol Obst 2006;94(Suppl 1):95-105.
47. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003;290:781-789
48. American Cancer Society. Guideline for Human Papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007;57:7-28.
49. Kulasingam SL, Pagliusi P, Myers E. Potential effects of decreased cervical cancer screening participation after HPV vaccination: an example from the U.S. Vaccine 2007;25:8110-8113 (Pubitemid 350046322)
50. Insinga R, Dasbach E, Allen S, Carides C, Myers E. Reductions in Human Papillomavirus-Disease Resource Use and Costs with Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccination: The FUTURE Study Economic Evaluation. Value Health 2008;16:1-11.
51. th International Papillomavirus Conference, May 8-14 2009, Malmö.
52. Pagliusi S, Lawson H, Singer A, Monsonego J. EUROGIN 2007 Patient Education Conference: Sharing experiences and action in cervical cancer prevention - an overview of 2007. Vaccine 2008;26S:A33-36.